CK在恶性黑色素瘤中的表达

 目的 检测CK在恶性黑色素瘤中的表达情况及意义。方法 应用免疫组化PV-9000二步法对18例恶性黑色素瘤进行CK、Vimentin、S-100、HMB45的检测。结果 在18例恶黑中CK的阳性表达率为67％(12／18)；其中原发性恶黑16例，CK和Vimentin的表达率分别为63％(10／16)、100％(16／16)；CPK与S-100，CK与HMB45两项均呈阳性表达者各占50％(8／16)，以上四项抗体均为阳性的表达率为44％(7／16)；两例转移性恶黑四项抗体均为阳性表达，占100％(2／2)。结论 CK在原发性和转移性恶黑中均有不同程度的阳性表达。     

乳腺癌bcl-2、Ki-67、p53表达及意义

目的：探讨bcl-2、Ki-67、p53蛋白在乳腺癌中的表达及其关系。方法：应用免疫组化SP方法，观察56例乳腺癌中的bcl-2、Ki-67、p53的表达情况。结果：bcl-2、Ki-67和p53在乳腺癌中表达率分别为63％，68％，52％，与乳腺癌分级及淋巴结转移密切相关（P＜0．05）。结论：bcl-2、Ki-67、p53的异常表达在乳腺肿瘤发生发展中起重要作用。     

p53蛋白和Ki-67在恶性纤维组织细胞瘤组织中的表达及意义

目的：研究p53蛋白和Ki-67在恶性纤维组织细胞瘤（malignant fibrous histiocytoma,MFH）组织中的表达及其临床意义.方法：应用免疫组化SP法检测50例MFH中p53和Ki 67的表达.结果：p53蛋白和Ki-67在MFH中表达阳性率分别为32.0%（16/50）和56.0%（28/50）;在有复发转移的患者中,p53蛋白和Ki-67的阳性率分别为48%（12/25）和68%（17/25）;在无复发转移的患者中,p53蛋白和Ki-67的阳性率分别为16.0%（4/25）和40.0%（10/25）;生存期＜5年的患者中,p53蛋白和Ki-67的阳性率分别为48.1%（13/27）和70.4%（19/27）,生存期＞5年的患者中p53蛋白和Ki-67的阳性率分别为17.4%（4/23）和39.1%（9/23）.p53蛋白和Ki-67与患者的复发转移及生存期显著相关,P＜0.05.p53蛋白与Ki-67的表达关系密切,P＜0.05.结论：p53蛋白和Ki-67的高表达与MFH的复发转移及患者生存期相关,两者的表达关系密切,并可作为MFH患者预后判断的两个指标.     

p53蛋白和Ki-67在恶性纤维组织细胞瘤组织中的表达及意义

目的:研究p53蛋白和Ki-67在恶性纤维组织细胞瘤(malignant fibrous histi-ocytoma,MFH)组织中的表达及其临床意义。方法:应用免疫组化SP法检测50例MFH中p53和Ki-67的表达。结果:p53蛋白和Ki-67在MFH中表达阳性率分别为32·0%(16/50)和56·0%(28/50);在有复发转移的患者中,p53蛋白和Ki-67的阳性率分别为48%(12/25)和68%(17/25);在无复发转移的患者中,p53蛋白和Ki-67的阳性率分别为16·0%(4/25)和40·0%(10/25);生存期<5年的患者中,p53蛋白和Ki-67的阳性率分别为48·1%(13/27)和70·4%(19/27),生存期>5年的患者中p53蛋白和Ki-67的阳性率分别为17·4%(4/23)和39·1%(9/23)。p53蛋白和Ki-67与患者的复发转移及生存期显著相关,P<0·05。p53蛋白与Ki-67的表达关系密切,P<0·05。结论:p53蛋白和Ki-67的高表达与MFH的复发转移及患者生存期相关,两者的表达关系密切,并可作为MFH患者预后判断的两个指标。肿瘤防治杂志,2005,12(19):1492-1494     

凋亡酶激活因子与p53及Ki-67在结直肠癌和结直肠腺癌组织中的表达

目的探讨凋亡酶激活因子1（Apaf-1）、p53和Ki-67在结直肠腺瘤、结直肠癌组织中的表达情况。方法采用SP染色法,检测结直肠癌、腺瘤组织中Apaf-1、p53和Ki-67的表达情况。结果结直肠癌淋巴结转移组中,Apaf-1、p53、Ki-67阳性表达率分别为22.7%、31.8%和90.9%,无淋巴结转移组分别为43.6%、89.7%和61.5%,差异均有统计学意义（均P〈0.05）。结直肠癌A、B期的Apaf-1、p53、Ki-67阳性表达率分别为43.6%、89.7%和61.5%,C、D期的Apaf-1、p53、Ki-67阳性表达率分别为27.7%、31.8%和90.9%。结直肠癌组织中Apaf-1阳性率（39.0%）低于腺瘤（88.0%）,p53阳性率（77.0%）和Ki-67阳性率（68.0%）均高于腺瘤（分别为49.0%、26.0%）,差异均有统计学意义（P〈0.05）。Apaf-1阳性表达与p53、Ki-67阳性表达均呈负相关（r1=-0.358,r2=-0.361,P〈0.01）。结论 Apaf-1、p53与Ki-67表达在结直肠癌、腺瘤的发生、发展与转移过程中有一定影响,对诊断结直肠癌有重要意义。     

非霍奇金淋巴瘤组织中突变型p53、bcl-2、Ki-67及survivin蛋白表达及临床意义

目的:探讨突变型p53、bcl-2、Ki-67、survivin在非霍奇金淋巴瘤(NHL)组织中的表达及其临床价值.方法:采用组织芯片技术及免疫组化SP法检测142例NHL和18例良性淋巴结病变组织中突变型p53、bcl-2、Ki-67、survivin蛋白的表达.结果:突变型p53、bcl-2、Ki-67、survivin蛋白在NHL中的表达阳性率分别为55.63%(79/142)、51.41%(73/142)、48.59%(69/142)和60.56%(86/142);与对照组相比具有非常显著性差异(P<0.01).在不同性别以及在不同细胞类别NHL中,突变型p53、bcl-2、Ki-67、survivin蛋白表达阳性率基本一致,统计分析无显著性差异(P>0.05);但在低年龄组、临床Ⅲ-Ⅳ期和高度恶性组突变型p53、bcl-2、Ki-67、survivin蛋白表达阳性率明显高于高年龄组、临床Ⅰ-Ⅱ期和低度恶性组,有显著性差异(P<0.05);突变型p53蛋白与Ki-67蛋白呈正相关(r=0.8769),survivin蛋白与bcl-2蛋白表达呈正相关(r=0.8846).结论:突变型p53、bcl-2、Ki-67、survivin蛋白在NHL组织中高表达,与NHL的发生与发展、细胞恶性程度和组织病理学等级密切相关.     

p53蛋白和增殖细胞核抗原在阑尾黏液性肿瘤和腹膜假黏液瘤中的表达及意义

  目的　研究p53蛋白和增殖细胞核抗原（Ki-67）表达与阑尾黏液性肿瘤临床病理特征之间的关系以及二者在肿瘤发生、发展中的作用。方法　选取解放军总医院病理科1993年5月至2007年10月收治的42例阑尾黏液性肿瘤患者手术标本组织蜡块,另取10例单纯性阑尾炎作为对照。应用PV6000免疫组织化学二步法,分别检测p53蛋白和Ki-67抗原的表达水平。结果　p53蛋白在阑尾黏液性肿瘤中表达阳性率[31.0 %（13／42）] 高于阑尾炎组[0（0／10）]（χ2＝4.127,P＝0.042）,在阑尾黏液腺癌组表达阳性率[40.0 %（12／30）]高于低级别黏液性肿瘤组[ 8.3 %（1／12）]（χ2＝4.0218,P＝0.044）。形成腹膜假黏液瘤组p53蛋白表达阳性率[45.5 %（10／22）]高于无腹膜假黏液瘤组[ 15.0 %（3／20）]（χ2＝4.5464,P＝0.033）。Ki-67抗原在阑尾黏液性肿瘤中标记阳性率[45.2 %（19／42）]高于阑尾炎组[10.0 %（1／10）]（χ2＝4.2374,P＝0.039）,而Ki-67抗原的表达与性别、年龄、是否形成腹膜假黏液瘤以及肿瘤病理类型等因素均无关（χ2值分别为0.0961、1.5910、1.6155、2.7776,均P＞0.05）。阑尾黏液性肿瘤中,p53蛋白阳性表达组Ki-67标记阳性率高于p53蛋白阴性组（χ2＝7.6299,P＝0.0057）。结论　p53基因的突变与阑尾黏液性肿瘤的发生、发展有一定关系 。Ki-67抗原表达可以反映出阑尾黏液性肿瘤增殖活性,但单独检测Ki-67不能作为鉴别肿瘤良性及判定恶性程度的指标。p53基因突变与Ki-67抗原表达存在相关性,联合检测p53蛋白、Ki-67抗原对于评估阑尾黏液性肿瘤的生物学行为,判断肿瘤恶性程度具有一定意义。     

Ki-67、p53、bcl-2的表达与恶性淋巴瘤自体造血干细胞移植预后的相关性

 目的　研究bcl-2、p53、Ki-67在恶性淋巴瘤组织中的表达以及与自体造血干细胞移植（AHSCT）预后的相关关系。方法　采用免疫组织化学IHC法检测33例行AHSCT治疗的患者淋巴瘤组织切片中Ki-67、p53、bcl-2的表达。并分析Ki-67、p53、bcl-2的表达与预后的相关性。生存率统计采用Kaplan-Meier生存曲线,Log-Rank检验,多因素分析采用COX风险回归模型。结果　p53 的表达与33例AHSCT患者预后无关,bcl-2阳性表达组和阴性表达组移植后3年无瘤生存率（DFS）分别为35.71 %和88.89 %（P＜0.05）;Ki-67阳性表达组和阴性表达组3年DFS分别为43.75 %和85.71 %（P <0.05）,提示bcl-2和Ki-67的表达与AHSCT的预后相关。COX多因素分析显示,Ki-67和bcl-2是影响淋巴瘤患者AHSCT后无瘤生存的相关因素（P＝0.0437）。结论　bcl-2、Ki-67蛋白阳性表达的淋巴瘤患者,AHSCT后易复发,可作为移植后预后判断的指标之一。Ki-67和bcl-2是影响淋巴瘤患者AHSCT无瘤生存的独立相关因素。     

p53、CyclinD1、Ki-67在甲状腺Hurthle细胞肿瘤组织中的表达及意义

目的:探讨p53、CyclinD1、Ki-67在甲状腺Hurthle细胞肿瘤组织中的表达及意义。方法:收集石蜡包埋Hurthle细胞肿瘤组织标本73例,免疫组化EnVision二步法检测CyclinD1、p53、Ki-67的表达并对患者进行随访。结果:依据是否有浸润及肿瘤直径,将Hurthle细胞肿瘤分为4组:1级27例（<2 cm,未见浸润）,2级18例（2~3.9 cm,未见浸润）,3级21例（≥4 cm,未见浸润）,4级7例（见有浸润,不论直径）。各组肿瘤中,p53阳性率为29.6%、55.6%、90.5%、100.0%;CyclinD1阳性率为7.4%、22.2%、52.4%、100.0%;Ki-67阳性率为0.0%、5.6%、9.5%、28.6%;p53及CyclinD1阳性率与肿瘤分级呈正相关。有效随访49例,其中2例复发,均表现为p53（+）/CyclinD1（+）,其中1例Ki-67>5%。结论:p53、CyclinD1、Ki-67在浸润性Hurthle细胞肿瘤中表达升高,检测p53、CyclinD1及Ki-67可能有助于Hurthle细胞肿瘤危险性评估。     

92例甲状腺癌中细胞增殖蛋白表达及其意义

目的：探讨甲状腺癌组织中p53、PCNA和Ki-67蛋白表达及其与临床病理的关系.方法：应用免疫组化sP法对92例甲状腺癌组织中p53、PCNA和Ki-67蛋白进行检测.结果：甲状腺癌组织p53阳性表达率为54.3%（50/92）,PCNA阳性表达率为56.9%（52/92）,Ki-67增殖指数为（12.01±3.32）%.p53、PC-NA过度表达及Ki-67增殖指数增加与浸润程度及淋巴结转移有关.结论：p53、PCNA和Ki-67蛋白表达与癌的浸润程度及淋巴结转移有关,p53、PCNA和Ki-67联合检测对甲状腺癌的早期诊断、预后判断及制定合理的临床治疗方案有重要意义.     

原发性无色素性恶性黑色素瘤的临床病理特征分析

目的探讨原发性无色素性恶性黑色素瘤的临床病理特点及免疫组化在鉴别诊断中的作用.方法对10例发生在不同部位的原发性无色素性恶性黑色素瘤进行光镜观察并对全部病例做免疫组化染色.结果光镜下的细胞形态的多样性,组织结构的复杂性,以均未找到黑色素颗粒为主要特点,免疫组化染色S-100蛋白、HMB45及Vimentin的阳性率分别100.0%、80.0%和70.0%.结论 10例原发性无色素性恶性黑色素瘤病理学诊断比较困难,组织结构的变化特点对其诊断具有重要意义,免疫组织化学对其诊断和鉴别诊断有重要价值.     

无色素性恶性黑色素瘤的免疫组化研究

目的探讨免疫组化在无色素性恶性黑色素瘤诊断和鉴别诊断的应用价值。方法回顾分析３７例可疑无色素性恶性黑色素瘤的组织学特点并进行免疫组化研究。结果３７例中１６例ＨＭＢ４５、Ｓ－１００和Ｖｉｍｅｎｔｉｎ阳性,证实为恶性黑色素瘤;２１例ＨＭＢ４５阴性,阴性者中７例ｃｙｔｏｋｅｒａｔｉｎ和ＣＥＡ、ＥＭＡ阳性,诊断为癌;８例ＬＣＡ阳性,诊断为淋巴瘤,６例Ｖｉｍｅｎｔｉｎ等阳性,诊断为肉瘤。结论ＨＭＢ４５和Ｓ－１００是无色素性恶性黑色素瘤的诊断性标记物,前者更具特异性。ＨＭＢ４５联合其它相关抗体可以作为无色素性恶黑鉴别诊断指标。     

47例皮肤黑色素瘤的临床与病理分析

目的 探讨黑色素瘤的临床与病理学特征,免疫组织化学特点,提高其早期诊断率。方法 分析47例黑色素瘤患者的临床资料和病理特征,15例免疫组织化学表型。结果 本组患者男31例,女16例,年龄16~83岁,平均年龄52岁。32例黑色素瘤均由病理组织学直接诊断,15例经免疫组织化学检查辅助确诊。结论 黑色素瘤具有黑色素细胞的某些临床和病理特点,早期诊断比较困难,常依赖于免疫组织化学技术,其中Vim和CEA、Ki-67和P53 、Bcl-2和P16具有重要鉴别诊断价值;HMB45和CyclinD1、MelanA和S-100、PCK和EMA具有重要诊断意义。     

Immunohistochemical profile of phyllodes tumors of the breast

The immunohistochemical profiles of 16 cases of phyllodes tumor of the breast (9 benign and 7 malignant) from 15 patients were examined by the labeled streptavidin biotin method. The expression of Ki-67, p53, bcl-2, alpha-smooth muscle actin (alpha-SMA), desmin, S-100 protein, estrogen receptor (ER), and progesterone receptor (PgR) was analyzed. The number of Ki-67-positive stromal cell nuclei of malignant phyllodes tumor were significantly more prominent than the benign tumors. The p53 expression on the stromal cell nuclei showed a significant difference between malignant and benign cases (86% vs 22%; p<0.05). bcl-2 was regularly seen on the luminal cell cytoplasm and stromal cell labeling showed no significant difference between malignant and benign cases (29% vs 33%). Stromal cells were alpha-SMA positive but refractory among cases, and desmin and S-100 protein were negative. PgR was expressed in all 16 cases and ER in most cases (12/16) the expression of which was restricted to luminal epithelial cell nuclei. These findings indicate that the Ki-67 labeling index and p53 expression in the stroma would be a good diagnostic parameter distinguishing benign tumors from malignant tumors. However, the absence of steroid receptor expression in stromal cells suggests the ineffectiveness of hormonal therapy for phyllodes tumor of the breast.     

Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours.

AIMS: The aim of this study was to determine whether expression of the oncoproteins p21, p53, E-cadherin (EC), cyclin D1, bcl-2 and Rb and the proliferation marker Ki-67 is predictive of malignant behaviour in gastrointestinal carcinoid tumours. METHODS: Immunohistochemical (IHC) staining was performed on carcinoid tumours from 41 patients (31 rectal, eight gastrointestinal, two appendiceal lesions). The six tumours that had invaded deeply into the muscularis propria or beyond, had metastasized to regional lymph nodes or had metastasized to a distant site were classified as the malignant group, and the other 35 tumours formed the benign group. IHC expression was compared between the two groups, and the prognostic value of each marker was assessed. RESULTS: Of the six tumours in the malignant group, 66.7% were p21 positive, 0% were p53 positive, 33.3% were EC positive, 100% were cyclin D1 positive, 33.3% were Rb positive, 16.7% were bcl-2 positive and 50% were Ki-67 positive. Of the 35 tumours in the benign group, 17.1% were p21 positive, 0% were p53 positive, 100% were EC positive, 94.3% were cyclin D1 positive, 8.6% were Rb positive, 17.1% were bcl-2 positive and 0% were Ki-67 positive. CONCLUSIONS: These data show that p53, cyclin D1, Rb, bcl-2 and Ki-67 staining does not correlate with malignant behaviour but that overexpression of p21 (P=0.02) and reduced staining of EC (P=0.005) do correlate with malignant behaviour. These two parameters may therefore be useful as prognostic indicators for gastrointestinal carcinoid tumours. Copyright Harcourt Publishers Limited.     

Biological analysis of gastrointestinal stromal tumors

The biological behaviour of a gastrointestinal stromal tumor (GIST) cannot be easily predicted from preoperative clinical examination alone. As a result, there is little standardization in the surgical treatment of GIST. In this study, we analyzed the clinicopathology and immunohistochemistry of 20 cases of GIST to clarify factors associated with tumors showing malignant potential. Immunohistochemical analysis of KIT, CD34, vimentin, alpha-smooth muscle actin (SMA), s-100, p53, ki-67, bcl-2 and bax expression was performed on 20 surgically resected GIST. An apoptotic index (AI) was calculated for each sample using a TdT-mediated dUTP-biotin nick end-labeling method. With regard to bcl-2, t(14;18) translocations were also investigated using a polymerase chain reaction based method. Finally, the relationship between these biological results and clinicopathological data was analyzed. Of the 20 cases studied, two patients died due to lung or liver metastasis. All cases stained positive for vimentin, nine cases were positive for alpha-SMA and three cases positive for s-100. All cases were stained for both KIT and CD34, which tended to correlate with malignant potential. There was significant difference in frequency of bcl-2 overexpression (p<0.05) and trend in Ki-67 labeling index (p=0.098) between benign and malignant cases. However, with regard to bcl-2, no chromosomal t(14;18) translocations were detected in four analyzed cases. In GIST, overexpression of bcl-2 may play an important role in increasing malignant potential. Furthermore, Ki-67 L.I. and bcl-2 overexpression may be useful in predicting malignant potential, and therefore help to determine the surgical treatment, follow-up manner, and the necessity of adjuvant therapy.     

Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study

BACKGROUND AND OBJECTIVES: Depth of invasion and stage of the disease are established prognostic indicators in cutaneous malignant melanoma. The role of other parameters is still an open problem. METHODS: In 93 consecutive patients with cutaneous malignant melanoma, the level of invasion, tumor thickness, ulceration, vascular invasion, lymphoplasmocytic infiltrates, and mitotic index were evaluated by histology. Expression of Ki-67 and PCNA proliferative antigens together with vimentin, S100, and HMB 45 proteins were assessed by immunohistochemistry. RESULTS AND CONCLUSIONS: Disease-free and overall survival were correlated with tumor stage, tumor thickness, level of invasion, macroscopic pattern, ulceration, vascular invasion, expression of HMB 45, PCNA, and Ki-67/MIB1. Stage, HMB 45, and PCNA were independent prognostic factors for disease-free survival, whereas tumor stage, tumor thickness, and expression of both proliferative antigens influenced overall survival independently. The variables studied demonstrated reciprocal correlation; therefore, analysis of many prognostic parameters in malignant melanoma could be recommended.